Developing novel biological therapies targeting myeloid malignancies 

The Wang Lab conducts acute myeloid leukemia (AML) preclinical research to find novel, synergistic treatments that target AML cells and leukemic stem cells in normal and hypoxic conditions. 

Our research focuses on a variety of mechanisms, including DNA repair, DNA damage, apoptosis, autophagy, mitophagy, and cell cycle.  

Image
Members of the Wang Lab

Join our team!

We currently seek candidates for a faculty position, Assistant or Associate Professor, specializing in Leukemia/Benign Hematology.

Apply Now!

Research Focus

AML is a highly heterogeneous disease, with a vital need for novel treatments that are targeted and better tolerated.

Read the Research

Clinical Trials

We’re studying several promising new drugs, including combination therapy with crenolanib and frontline treatment with gilteritinib.

See the Science

People

Get to know our principal investigator and lab members.

Meet our Team

Publications

Check out the latest articles and abstracts from Dr. Wang’s team.

View Citations
Image
Dr. Wang in the lab.

"If you're diagnosed with cancer, you can't wait six to 12 months for the FDA to approve a drug. You need it now." 

Dr. Wang on OncLiveTVDr. Wang on VJHEMONC

Contact Information

Connect with the Wang Lab

EmailTwitterLinkedIn

Department of Immunology 
Roswell Park Comprehensive Cancer Center 
Elm and Carlton Streets 
Buffalo, NY 14263